The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.
November 27th 2023
Belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival compared with daratumumab plus B-Vd in the second-line treatment of patients with relapsed or refractory multiple myeloma, meeting the primary end point of the phase 3 DREAMM-7 trial.
November 20th 2023
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
December 8, 2023
Register Now!
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
View More
Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in the Treatment of MPNs
View More
Oncology Consultations®: Leveraging Clinical Data and Trials to Inform Treatment for Patients with PV
View More
How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult
View More
Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GVHD?
View More
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow
View More
40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Oncology Roundtable: Treating MF and PV in 2023
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Keeping Pace with Rapid Advancements in Multiple Myeloma Care
View More
Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in GvHD Prevention and Treatment
View More
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Medical Crossfire®: How Does the Evidence Inform Your RCC Sequence? The Experts Share Clinical Perspectives
View More
From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis
View More
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
View More
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
Clinical Vignettes™: Integrating Novel CAR T-Cell Therapies Across Lymphoid Malignancies with an Eye Toward the Future of Care
View More
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Elranatamab Approaches EU Approval for Heavily Pretreated Relapsed/Refractory Multiple Myeloma
November 1st 2023The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of elranatamab-bcmm for the treatment of adult patients with relapsed/refractory multiple myeloma who were previously treated with 3 or more lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and who experienced disease progression on their last therapy.
Dr Hillengass on the Influence of Exercise on Functional Performance in Multiple Myeloma
October 10th 2023Jens Hillengass, MD, PhD, professor, discusses the influence of physical activity on functional performance for patients with multiple myeloma, according to results from a 2-arm, nonrandomized pilot exercise study.
Venetoclax Plus Dexamethasone Misses PFS End Point in t(11;14)+ R/R Multiple Myeloma
The combination of venetoclax and dexamethasone failed to significantly improve progression-free survival over pomalidomide plus dexamethasone in patients with t(11;14)-positive, relapsed or refractory multiple myeloma who have previously received at least 2 therapies.
Elranatamab Represents Another Off-the-Shelf Option for Heavily Pretreated R/R Myeloma
Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and sheds light on the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment of this patient population.
Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple Myeloma
October 3rd 2023Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.
Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma
September 30th 2023The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.
Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features
September 30th 2023Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
CD38/48 Upregulation With Tazemetostat May Overcome Daratumumab Resistance in Multiple Myeloma
September 29th 2023The EZH2 inhibitor tazemetostat may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.
IberVd Elicits Durable Responses in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
The combination of iberdomide plus bortezomib and dexamethasone produced deep responses with a manageable toxicity profile in patients with transplant-ineligible, newly diagnosed multiple myeloma, according to data from the phase 1/2 CC-220-MM-001 trial presented at the 2023 International Myeloma Society Annual Meeting.
Although quadruplet combination regimens featuring daratumumab demonstrated consistent efficacy in the treatment of patients with newly diagnosed multiple myeloma, certain prognostic factors were associated with early relapse, according to data from a retrospective analysis presented at the 2023 International Myeloma Society Annual Meeting.
Teclistamab Delivers Comparable Efficacy Between Real-World and MajesTEC-1 Myeloma Populations
September 29th 2023Treatment with teclistamab-cqyv in real-world patients with relapsed/refractory multiple myeloma elicited similar efficacy results and a comparable safety profile to findings from the phase 1/2 Majes-TEC-1 trial.
Daratumumab Plus KRd With Tandem Transplant Sustains Efficacy in High-Risk, Newly Diagnosed Myeloma
September 29th 2023Induction daratumumab, carfilzomib, lenalidomide, and dexamethasone followed by consolidation double transplant sustained efficacy and safety in patients with high-risk, newly diagnosed multiple myeloma.
PVd Extends OS and PFS in Relapsed/Refractory Multiple Myeloma
Treatment with the combination of pomalidomide, bortezomib, and dexamethasone conferred a small, statistically nonsignificant overall survival benefit compared with bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma
Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.